New immunosuppressive protocols with the advent of novel biological drugs

Transplantation

Volumn 88, Issue SUPPL. 3, 2009, Pages

  Cruzado, Josep M ^a   Bestard, Oriol ^a   Grinyó, Josep M ^a  

^a HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

Author keywords

ATG; Belatacept; CD40; Immunosuppression.

Indexed keywords

ABATACEPT; BASILIXIMAB; BELATACEPT; CALCINEURIN INHIBITOR; CD40 LIGAND; COMPLEMENT COMPONENT C5 INHIBITOR; CORTICOSTEROID; CYCLOSPORIN A; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RAPAMYCIN; THYMOCYTE ANTIBODY;

ANTIBODY PRODUCTION; B LYMPHOCYTE; CELL SURVIVAL; CHRONIC ALLOGRAFT NEPHROPATHY; CLINICAL TRIAL; DRUG MECHANISM; DRUG SAFETY; DRUG WITHDRAWAL; GRAFT REJECTION; GRAFT SURVIVAL; HUMAN; HUMORAL IMMUNITY; KIDNEY TRANSPLANTATION; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; SHORT SURVEY; UNSPECIFIED SIDE EFFECT;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD28; ANTIGENS, CD80; B-LYMPHOCYTES; CELL SURVIVAL; GRAFT REJECTION; HLA ANTIGENS; HUMANS; IMMUNOCONJUGATES; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; LYMPHOCYTE DEPLETION; T-LYMPHOCYTES; T-LYMPHOCYTES, REGULATORY;

EID: 70349110123     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e3181af666c     Document Type: Short Survey

References (46)

1. Halloran PF. Immunosuppressive drugs for kidney transplantation. N Engl J Med 2004; 351: 2715.
2. Nankivell BJ, Chapman JR. Chronic allograft nephropathy: Current concepts and future directions. Transplantation 2006; 81: 643.
3. Meier-Kriesche HU, Schold JD, Srinivas TR, et al. Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era. Am J Transplant 2004; 4: 378.
4. Samaniego M, Becker BN, Djamali A. Drug insight: Maintenance im-munosuppression in kidney transplant recipients. Nat Clin Pract Neph-rol 2006; 2: 688.
5. Vincenti F, Schena FP, Paraskevas S, et al. FREEDOM Study Group. A randomized, multicenter study of steroid avoidance, early steroid withdrawal or standard steroid therapy in kidney transplant recipients. Am J Transplant 2008; 8: 307.
6. Ekberg H, Tedesco-Silva H, Demirbas A, et al. Reduced exposure to cal-cineurin inhibitors in renal transplantation. N Engl J Med 2007; 357: 2562.
7. Ekberg H, Grinyo J, Nashan B, et al. Cyclosporine sparing with myco-phenolate mofetil, daclizumab and corticosteroids in renal allograft recipients: The CAESAR Study. Am J Transplant 2007; 7: 560.
8. Wali RK, Weir MR. Chronic allograft dysfunction: Can we use mammalian target of rapamycin inhibitors to replace calcineurin inhibitors to preserve graft function? Curr Opin Organ Transplant 2008; 13: 614.
9. Vincenti F, Kirk AD. What's next in the pipeline. Am J Transplant 2008; 8: 1972.
10. Waldmann H, Adams E, Cobbold S. Reprogramming the immune system: Co-receptor blockade as a paradigm for harnessing tolerance mechanisms. Immunol Rev 2008; 223: 361.
11. Yabu JM, Vincenti F. Novel immunosuppression: Small molecules and biologics. Semin Nephrol 2007; 27: 479.
12. Scandling JD, Busque S, Dejbakhsh-Jones S, et al. Tolerance and chi-merism after renal and hematopoietic-cell transplantation. N Engl J Med 2008; 358: 362.
13. Kawai T, Cosimi AB, Spitzer TR, et al. HLA-mismatched renal transplantation without maintenance immunosuppression. N Engl J Med 2008; 358: 353.
14. Sayegh MH, Turka LA. The role of T-cell costimulatory activation pathways in transplant rejection. N Engl J Med 1998; 338: 1813.
15. Larsen CP, Pearson TC, Adams AB, et al. Rational development of LEA29Y (belatacept), a high-affinity variant of CTLA4-Ig with potent immunosuppressive properties. Am J Transplant 2005; 5: 443.
16. Vincenti F, Larsen C, Durrbach A, et al. Costimulation blockade with belatacept in renal transplantation. N Engl J Med 2005; 353: 770.
17. Vincenti F. Costimulation blockade in autoimmunity and transplantation. J Allergy Clin Immunol 2008; 121: 299-306; quiz 307-308. Links.
18. Bluestone JA. CTLA-4Ig is finally making it: A personal perspective. Am J Transplant 2005; 5: 423.
19. Bluestone JA, Liu W, Yabu JM, et al. The effect of costimulatory and interleukin 2 receptor blockade on regulatory T cells in renal transplantation. Am J Transplant 2008; 8: 2086.
20. Beiras-Fernandez A, Thein E, Hammer C. Induction of immunosup-pression with polyclonal antithymocyte globulins: An overview. Exp Clin Transplant 2003; 1: 79.
21. Lowsky R, Takahashi T, Liu YP, et al. Protective conditioning for acute graft-versus-host disease. N Engl J Med 2005; 353: 1321.
22. Genestier L, Fournel S, Flacher M, et al. Induction of Fas (Apo-1, CD95)-mediated apoptosis of activated lymphocytes by polyclonal an-tithymocyte globulins. Blood 1998; 91: 2360.
23. Michallet MC, Preville X, Flacher M, et al. Functional antibodies to leukocyte adhesion molecules in antithymocyte globulins. Transplantation 2003; 75: 657.
24. Zand MS, Vo T, Huggins J, et al. Polyclonal rabbit antithymocyte globulin triggers B-cell and plasma cell apoptosis by multiple pathways. Transplantation 2005; 79: 1507.
25. Brennan DC. Faith supported by reason: Mechanistic support for the use of polyclonal antibodies in transplantation. Transplantation 2003; 75: 577.
26. Lopez M, Clarkson MR, Albin M, et al. A novel mechanism of action for anti-thymocyte globulin: Induction of CD4-CD25-Foxp3- regulatory T cells. J Am Soc Nephrol 2006; 17: 2844.
27. Neujahr DC, Chen C, Huang X, et al. Accelerated memory cell ho-meostasis during T cell depletion and approaches to overcome it. J Im-munol 2006; 176: 4632.
28. Minaminura K, Gao W, Maki T. CD4- regulatory T cells are spread from deletion by antilymphocyte serum, a polyclonal anti-T cell antibody. J Immunol 2006; 176: 4125.
29. Zheng XX, Sanchez-Fueyo A, Domenig C, et al. Favorably tipping the balance between cytopathic and regulatory T cells create transplantation tolerance. Immunity 2003; 19: 503.
30. Rothstein DM. Immunosuppression and regulation: Cast in new light? J Am Soc Nephrol 2006; 17: 2644.
31. Racusen LC, Solez K, Colvin RB, et al. The Banff 97 working classification of renal allograft pathology. Kidney Int 1999; 55: 713.
32. Komatsu N, Hori S, Komatsu N, et al. Full restoration of peripheral Foxp3- regulatory T cell pool by radioresistant host cells in scurfy bone marrow chimeras. Proc Natl Acad Sci USA 2007; 104: 8959.
33. Moxham VF, Karegli J, Phillips RE, et al. Homeostatic proliferation of lymphocytes results in augmented memory-like function and accelerated allograft rejection. J Immunol 2008; 180: 3910.
34. Yang J, Zhang J, Walsh PT, et al. Allograft rejection mediated by CD4- memory T cells is resistant to regulation by both naive and alloantigen-primed CD4-CD25- regulatory T cells. Am J Transplant 2006; 6(suppl 2): 81.
35. Brennan DC, Daller JA, Lake KD, et al; Thymoglobulin Induction Study Group. Rabbit antithymocyte globulin versus basiliximab in renal transplantation. N Engl J Med 2006; 355: 1967.
36. Büchler M, Caillard S, Barbier S, et al; SPIESSER Group. Sirolimus versus cyclosporine in kidney recipients receiving thymoglobulin, my-cophenolate mofetil and a 6-month course of steroids. Am J Transplant 2007; 7: 2522.
37. Bestard O, Cruzado JM, Mestre M, et al. Achieving donor-specific hy-poresponsiveness is associated with FOXP3-regulatory T cell recruitment in human renal allograft infiltrates. J Immunol 2007; 179: 4901.
38. Bestard O, Cruzado JM, Rama I, et al. Presence of FoxP3-regulatory T cells predicts outcome of subclinical rejection of renal allografts. J Am Soc Nephrol 2008; 19: 2020.
39. Cruzado JM, Bestard O, Grinyó JM. Control of antidonor antibody production post-transplantation: Conventional and novel immunosuppressive therapies. Contrib Nephrol 2009; 162: 117.
40. Bestard O, Nickel P, Cruzado JM, et al. Circulating alloreactive T cells correlate with graft function in longstanding renal transplant recipients. J Am Soc Nephrol 2008; 19: 1419.
41. Nickeleit V, Andreoni K. The classification and treatment of antibody-mediated renal allograft injury: Where do we stand? Kidney Int 2007; 71: 7.
42. Rother RP, Arp J, Jiang J, et al. C5 blockade with conventional immu-nosuppression induces long-term graft survival in presensitized recipients. Am J Transplant 2008; 8: 1129.
43. Csencsits K, Burrell BE, Lu G, et al. The classical component pathway in transplantation: Unanticipated protective effects of C1q and role in inductive antibody therapy. Am J Transplant 2008; 8: 1.
44. Pluvinet R, Olivar R, Krupinski J, et al. CD40: An upstream master switch for endothelial cell activation uncovered by RNAi-coupled transcriptional profiling. Blood 2008; 112: 3624.
45. Pluvinet R, Petriz J, Torras J, et al. RNAi-mediated silencing of CD40 prevents leukocyte adhesion on CD154-activated endothelial cells. Blood 2004; 104: 3642.
46. Xu H, Yan J, Huang Y, et al. Costimulatory blockade of CD154-CD40 in combination with T-cell lymphodepletion results in prevention of allogeneic sensitization. Blood 2008; 111: 3266.